

Hanna Shevalye

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3814440/publications.pdf>

Version: 2024-02-01

33
papers

1,242
citations

331259

21
h-index

395343

33
g-index

33
all docs

33
docs citations

33
times ranked

1539
citing authors

#	ARTICLE	IF	CITATIONS
1	Interaction between magnesium and methylglyoxal in diabetic polyneuropathy and neuronal models. <i>Molecular Metabolism</i> , 2021, 43, 101114.	3.0	7
2	Effect of mitoquinone on liver metabolism and steatosis in obese and diabetic rats. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00701.	1.1	7
3	Characterization of Mice Ubiquitously Overexpressing Human 15-Lipoxygenase-1: Effect of Diabetes on Peripheral Neuropathy and Treatment with Menhaden Oil. <i>Journal of Diabetes Research</i> , 2021, 2021, 1-11.	1.0	5
4	Progressive Loss of Corneal Nerve Fibers and Sensitivity in Rats Modeling Obesity and Type 2 Diabetes Is Reversible with Omega-3 Fatty Acid Intervention: Supporting Cornea Analyses as a Marker for Peripheral Neuropathy and Treatment. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 1367-1384.	1.1	21
5	Effect of mitoquinone (Mito-Q) on neuropathic endpoints in an obese and type 2 diabetic rat model. <i>Free Radical Research</i> , 2020, 54, 311-318.	1.5	19
6	Effect of Early and Late Interventions with Dietary Oils on Vascular and Neural Complications in a Type 2 Diabetic Rat Model. <i>Journal of Diabetes Research</i> , 2019, 2019, 1-12.	1.0	12
7	Determination of peripheral neuropathy in high-fat diet fed low-dose streptozotocin-treated female C57Bl/6J mice and Sprague-Dawley rats. <i>Journal of Diabetes Investigation</i> , 2018, 9, 1033-1040.	1.1	28
8	Vascular and Neural Complications in Type 2 Diabetic Rats: Improvement by Sacubitril/Valsartan Greater Than Valsartan Alone. <i>Diabetes</i> , 2018, 67, 1616-1626.	0.3	24
9	Effect of dietary oils on peripheral neuropathy-related endpoints in dietary obese rats. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2018, Volume 11, 117-127.	1.1	21
10	Effect of Dietary Content of Menhaden Oil with or without Salsalate on Neuropathic Endpoints in High-Fat-Fed/Low-Dose Streptozotocin-Treated Sprague Dawley Rats. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-9.	1.0	14
11	Impaired Corneal Sensation and Nerve Loss in a Type 2 Rat Model of Chronic Diabetes Is Reversible With Combination Therapy of Menhaden Oil, α -Lipoic Acid, and Enalapril. <i>Cornea</i> , 2017, 36, 725-731.	0.9	28
12	Effect of tempol on peripheral neuropathy in diet-induced obese and high-fat fed/low-dose streptozotocin-treated C57Bl/6J mice. <i>Free Radical Research</i> , 2017, 51, 360-367.	1.5	20
13	Early vs. late intervention of high fat/low dose streptozotocin treated C57Bl/6J mice with enalapril, α -lipoic acid, menhaden oil or their combination: Effect on diabetic neuropathy related endpoints. <i>Neuropharmacology</i> , 2017, 116, 122-131.	2.0	25
14	Effect of Fish oil Vs. Resolvin D1, E1, Methyl Esters of Resolvins D1 or D2 on Diabetic Peripheral Neuropathy. <i>Journal of Neurology & Neurophysiology</i> , 2017, 08, .	0.1	17
15	Effect of Treatment with Salsalate, Menhaden Oil, Combination of Salsalate and Menhaden Oil, or Resolvin D1 of C57Bl/6J Type 1 Diabetic Mouse on Neuropathic Endpoints. <i>Journal of Nutrition and Metabolism</i> , 2016, 2016, 1-11.	0.7	20
16	Effect of diet-induced obesity or type 1 or type 2 diabetes on corneal nerves and peripheral neuropathy in C57Bl/6J mice. <i>Journal of the Peripheral Nervous System</i> , 2015, 20, 24-31.	1.4	54
17	Effect of enriching the diet with menhaden oil or daily treatment with resolvin D1 on neuropathy in a mouse model of type 2 diabetes. <i>Journal of Neurophysiology</i> , 2015, 114, 199-208.	0.9	74
18	Effect of glycemic control on corneal nerves and peripheral neuropathy in streptozotocin-induced diabetic C57Bl/6J mice. <i>Journal of the Peripheral Nervous System</i> , 2014, 19, 205-217.	1.4	41

#	ARTICLE	IF	CITATIONS
19	Peroxynitrite and protein nitration in the pathogenesis of diabetic peripheral neuropathy. <i>Diabetes/Metabolism Research and Reviews</i> , 2014, 30, 669-678.	1.7	67
20	Endoplasmic Reticulum Stress Plays a Key Role in the Pathogenesis of Diabetic Peripheral Neuropathy. <i>Diabetes</i> , 2013, 62, 944-952.	0.3	160
21	Na ⁺ /H ⁺ exchanger 1 inhibition reverses manifestation of peripheral diabetic neuropathy in type 1 diabetic rats. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2013, 305, E396-E404.	1.8	19
22	Prediabetic Nephropathy as an Early Consequence of the High-Calorie/High-Fat Diet: Relation to Oxidative Stress. <i>Endocrinology</i> , 2012, 153, 1152-1161.	1.4	35
23	Metanx Alleviates Multiple Manifestations of Peripheral Neuropathy and Increases Intraepidermal Nerve Fiber Density in Zucker Diabetic Fatty Rats. <i>Diabetes</i> , 2012, 61, 2126-2133.	0.3	38
24	Interplay of sorbitol pathway of glucose metabolism, 12/15-lipoxygenase, and mitogen-activated protein kinases in the pathogenesis of diabetic peripheral neuropathy. <i>Biochemical Pharmacology</i> , 2012, 83, 932-940.	2.0	32
25	Baicalein alleviates diabetic peripheral neuropathy through inhibition of oxidative and nitrosative stress and p38 MAPK activation. <i>Experimental Neurology</i> , 2011, 230, 106-113.	2.0	84
26	Evaluation of PMI-5011, an ethanolic extract of <i>Artemisia dracunculus</i> L., on peripheral neuropathy in streptozotocin-diabetic mice. <i>International Journal of Molecular Medicine</i> , 2011, 27, 299-307.	1.8	27
27	PARP inhibition alleviates diabetes-induced systemic oxidative stress and neural tissue 4-hydroxynonenal adduct accumulation: Correlation with peripheral nerve function. <i>Free Radical Biology and Medicine</i> , 2011, 50, 1400-1409.	1.3	76
28	Poly(ADP-ribose) polymerase (PARP) inhibition counteracts multiple manifestations of kidney disease in long-term streptozotocin-diabetic rat model. <i>Biochemical Pharmacology</i> , 2010, 79, 1007-1014.	2.0	35
29	Role of 12/15-lipoxygenase in nitrosative stress and peripheral prediabetic and diabetic neuropathies. <i>Free Radical Biology and Medicine</i> , 2010, 49, 1036-1045.	1.3	49
30	New Therapeutic and Biomarker Discovery for Peripheral Diabetic Neuropathy: PARP Inhibitor, Nitrotyrosine, and Tumor Necrosis Factor- α . <i>Endocrinology</i> , 2010, 151, 2547-2555.	1.4	77
31	Poly(ADP-ribose) polymerase-1 (PARP-1) gene deficiency alleviates diabetic kidney disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2010, 1802, 1020-1027.	1.8	36
32	Different Roles of 12/15-Lipoxygenase in Diabetic Large and Small Fiber Peripheral and Autonomic Neuropathies. <i>American Journal of Pathology</i> , 2010, 177, 1436-1447.	1.9	46
33	Poly(Adenosine 5'-Diphosphate-Ribose) Polymerase Inhibition Counteracts Multiple Manifestations of Experimental Type 1 Diabetic Nephropathy. <i>Endocrinology</i> , 2009, 150, 5273-5283.	1.4	24